NYSE:MRX Medicis Pharmaceutical (MRX) Stock Price, News & Analysis → FW: 234x Gain (From Weiss Ratings) (Ad) Free MRX Stock Alerts Notice: This company recently went public with an IPO on Thursday, April 25th 2024. They issued 15,384,615 shares at $19.00 per share. We will continue to update data for MRX as it becomes available. Add Share Share Today's Range$18.50▼$19.3050-Day Range N/A52-Week Range N/AVolume525,193 shsAverage Volume1.99 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisSocial MediaStock AnalysisSocial Media Get Medicis Pharmaceutical alerts: Email Address Ad Paradigm PressDems have chosen Biden replacement?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.See who it is HERE. About Medicis Pharmaceutical Stock (NYSE:MRX)Medicis Pharmaceutical Corporation (Medicis) together with its wholly owned subsidiaries is an independent specialty pharmaceutical company engaged in the development and marketing of products for the treatment of dermatological and aesthetic conditions in the United States and Canada. Medicis offers a range of products addressing various conditions or aesthetic improvements, including facial wrinkles. Its brands are DYSPORT (abobotulinumtoxinA) 300 Units for Injection, PERLANE Injectable Gel, RESTYLANE Injectable Gel, SOLODYN (minocycline HCl, USP) Extended Release Tablets, VANOS (fluocinonide) Cream 0.1%, ZIANA (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel and ZYCLARA (imiquimod) Cream 3.75% and 2.5%. As of December 31, 2011, it offered 27 branded products. On December 2, 2011, it acquired Graceway Pharmaceuticals, LLC (Graceway). On November 1, 2011, Medicis sold Medicis Technologies Corporation, formerly LipoSonix, Inc., to Solta Medical, Inc. (Solta).Read More Ad Paradigm PressDems have chosen Biden replacement?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.See who it is HERE. MRX Stock News HeadlinesApril 29, 2024 | investorplace.comWhy Is Marex (MRX) Stock On the Move Today?April 25, 2024 | finance.yahoo.comIPOs Shine Bright in a Tough Day for StocksMay 3, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).April 24, 2024 | reuters.comBritish commodities platform Marex prices US IPO at $1.35 bln valuationApril 24, 2024 | globenewswire.comMarex Group plc Announces Pricing of Initial Public OfferingApril 15, 2024 | globenewswire.comMarex Group plc Announces Launch of Initial Public OfferingDecember 20, 2023 | seekingalpha.comTLPPF Telix Pharmaceuticals LimitedDecember 5, 2023 | finance.yahoo.comPrime Therapeutics announces Ken Bodmer as chief financial officerMay 3, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).November 1, 2023 | morningstar.comAcelRx Pharmaceuticals Inc ACRXOctober 5, 2023 | finance.yahoo.comPRIME THERAPEUTICS/MAGELLAN RX EXPANDS PARTNERSHIP WITH MHK TO MANAGE MEMBER ENROLLMENT WITH MARKETPROMINENCE TECHNOLOGYMarch 27, 2023 | uk.finance.yahoo.comAnanda Developments Plc - Result of General MeetingMarch 23, 2023 | bizjournals.comBoston Pharmaceuticals NewsMarch 9, 2023 | finanznachrichten.deAnanda Developments Plc - Acquisition of MRX and SubscriptionSeptember 20, 2022 | markets.businessinsider.comXpira Pharmaceuticals Inc. Receives FDA Approval For Psilocybin Trial IND ApplicationAugust 31, 2022 | thestreet.comMedicis to Acquire InamedJanuary 22, 2022 | thestreet.comMedicis Stock Hits New 52-Week High (MRX)January 5, 2022 | investing.comMedicis Pharmaceutical Corp (MRX)See More Headlines Receive MRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medicis Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorFinance Industry N/A Sub-IndustryN/A Current SymbolNYSE:MRX CUSIPN/A CIK859368 Webwww.Medicis.com Phone+1-212-5992000FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesRobert Roswell Chai-Onn (Age 44)Executive Vice President, General Counsel, Secretary, Director Howard Bradley Schiller (Age 53)Officer, Director Ryan WeldonOfficer, Director MRX Stock Analysis - Frequently Asked Questions When did Medicis Pharmaceutical IPO? Medicis Pharmaceutical (MRX) raised $292 million in an initial public offering (IPO) on Thursday, April 25th 2024. The company issued 15,384,615 shares at $19.00 per share. When does Medicis Pharmaceutical's quiet period expire? Medicis Pharmaceutical's quiet period expires on Tuesday, June 4th. Medicis Pharmaceutical had issued 15,384,615 shares in its initial public offering on April 25th. The total size of the offering was $292,307,685 based on an initial share price of $19.00. During Medicis Pharmaceutical's quiet period, underwriters and any insiders involved in the IPO are restricted from issuing any research reports for the company because of SEC regulations. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company. This page (NYSE:MRX) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldUrgent Nvidia WarningAltimetryAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldThe Gold Grab of the CenturyColonial MetalsUrgent alert: open this for a huge profit potentialTimothy SykesThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicis Pharmaceutical Corp Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.